NCT03872232View on ClinicalTrials.gov

Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

February 26, 2019

Primary Completion Date

August 12, 2020

Study Completion Date

August 12, 2020

Conditions
HypercholesterolemiaHypertension
Interventions
DRUG

Ezetimibe/Rosuvastatin

PO, Once daily(QD), 8weeks

DRUG

Telmisartan

PO, Once daily(QD), 8weeks

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT03872232 - Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan | Biotech Hunter | Biotech Hunter